Use of chimeric antigen receptor modified cells to treat cancer
AssigneeInnovative Cellular Therapeutics, Inc.
InventorsLei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
Claims8
An isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain that binds to a prolactin receptor, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein:
- the antigen binding domain comprises the amino acid sequence of SEQ ID NO:
- 8, or
- the CAR comprises the amino acid sequence of SEQ ID NO:
- 42.
A composition comprising a population of T cells comprising a nucleic acid sequence encoding a CAR, wherein the CAR comprises an antigen binding domain that binds to a prolactin receptor, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein:
- the antigen binding domain comprises the amino acid sequence of SEQ ID NO:
- 8, or
- the CAR comprises the amino acid sequence of SEQ ID NO:
- 42.
A method for stimulating an anti-tumor immune response in a subject, the method comprising administrating to the subject an effective amount of a pharmaceutical composition comprising a population of human T cells comprising a nucleic acid sequence encoding a CAR, wherein the CAR comprises an antigen binding domain that binds to a prolactin receptor, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein:
- the antigen binding domain comprises the amino acid sequence of SEQ ID NO:
- 8, or
- the CAR comprises the amino acid sequence of SEQ ID NO:
- 42.
Dependencies are inferred from the claim text.